IC
TVRD

Ikarian Capital’s Tvardi Therapeutics TVRD Stock Holding History

Ikarian Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,000
Closed -$740K – 235
2025
Q3 		$740K Buy
+19,000
New +$541K 0.07% 127
2021
Q2 		– Sell
-23,517
Closed -$18.4M – 301
2021
Q1 		$18.4M Buy
23,517
+15,136
+181% +$10.4M 0.62% 35
2020
Q4 		$4.57M Buy
8,381
+6,770
+420% +$3.55M 0.2% 100
2020
Q3 		$738K Buy
1,611
+1,067
+196% +$620K 0.05% 135
2020
Q2 		$335K Hold
544
– – 0.03% 142
2020
Q1 		$259K Buy
544
+52
+11% +$28.3K 0.02% 143
2019
Q4 		$285K Buy
+492
New +$345K 0.05% 97

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Ikarian Capital's TVRD Position: Q3 2021 in Review

Ikarian Capital sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 815 shares — an estimated $418K sold.

Ikarian Capital first reported a position in TVRD in Q1 2020 and held it in 6 quarters. The position peaked at $12.1M in Q1 2021. 169 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

  • Ikarian Capital reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Ikarian Capital sold 815 Tvardi Therapeutics shares in Q3 2021, an estimated $418K.
  • Ikarian Capital first reported a position in Tvardi Therapeutics in Q1 2020 and held it in 6 quarters.
  • Ikarian Capital's Tvardi Therapeutics position peaked at $12.1M in Q1 2021.
  • 169 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.